Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AvitaROCO:4735 +2.52%72 EV-to-EBIT is 4.04 as of Sep. 13, 2026, which is 59% below its 10-year median of 9.95. GuruFocus rates ROCO:4735 with a GF Score™ of 72/100 and a GF Value™ of NT$33.33 (Fairly Valued). The stock has 10 warning signs investors should review. Among 474 Medical Devices & Instruments companies, Avita ranks better than 93.25% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Avita's Enterprise Value is NT$983.5 Mil.
Avita's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$243.6 Mil. Therefore, Avita's EV-to-EBIT for today is 4.04.
The historical rank and industry rank for Avita's EV-to-EBIT or its related term are showing as below:
ROCO:4735'
s EV-to-EBIT Range Over the Past 10 Years
Min: 2.03 Med: 9.95 Max: 63.7
Current: 4.04
During the past 13 years, the highest EV-to-EBIT of Avita was 63.70. The lowest was 2.03. And the median was 9.95.
ROCO:4735's EV-to-EBIT is ranked better than 93.25% of 474
companies
in the Medical Devices & Instruments industry
Industry Median: 18.005
vs ROCO:4735: 4.04
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Avita's Enterprise Value for the quarter that ended in Jun. 2026 was NT$777.5 Mil.
Avita's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$243.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avita EV-to-EBIT Related Terms
Avita EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Avita's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Avita's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avita EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Avita's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Avita's EV-to-EBIT falls into.
Avita's current Enterprise Value is NT$983.5 Mil.
Avita's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$243.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avita (ROCO:4735) has a EV-to-EBIT of 4.04 as of Sep. 13, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Avita and its competitors. This is 59% below median its historical median of 9.95. Over the past decade, Avita's EV-to-EBIT has ranged from 2.03 to 63.70. According to the industry distribution chart, Avita ranks #32 out of 474 companies in the Medical Devices & Instruments industry, placing it in the top 6.8%.
Is Avita's EV-to-EBIT too high?
Avita's current EV-to-EBIT of 4.04 is 59% below median its 10-year median of 9.95. Over the past 10 years, this metric has ranged from a low of 2.03 to a high of 63.70. The Medical Devices & Instruments industry median EV-to-EBIT is 18.01. Avita's value of 4.04 is 77.6% below this industry median. Based on the distribution chart, Avita ranks #32 out of 474 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Avita has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Avita's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Avita ranks #32 out of 474 companies for EV-to-EBIT. This places Avita in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.01. Avita's value of 4.04 is 77.6% below this benchmark. Historically, Avita's own EV-to-EBIT has ranged from 2.03 to 63.70 over the past decade. While the company's 10-year median is 9.95 vs. the industry median of 18.01, Avita has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.01, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avita's current EV-to-EBIT of 4.04 is 77.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Avita and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avita's current EV-to-EBIT is 4.04, which is 59% below median its own 10-year median of 9.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avita stock overvalued right now?
Based on GuruFocus' analysis, Avita (ROCO:4735) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.33, compared to a current price of NT$36.55 — trading 9.7% above its estimated fair value. The current EV-to-EBIT is 4.04, which is 59% below median its 10-year median of 9.95 and 77.6% below the Medical Devices & Instruments industry median of 18.01. Avita's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Avita (ROCO:4735), the current EV-to-EBIT is 4.04 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avita (ROCO:4735) Overvalued in 2026?
Based on GuruFocus' analysis, Avita stock appears to be overvalued.
The current stock price of NT$36.55 is trading 9.7% above its estimated GF Value™ of NT$33.33.
GuruFocus considers Avita to be Fairly Valued.
Key valuation signals for ROCO:4735:
EV-to-EBIT: 4.04 (59% below median its 10-year median of 9.95)
GF Value™: NT$33.33 vs. price of NT$36.55 (9.7% above fair value)
Industry Position: 77.6% below the Medical Devices & Instruments median (#32 of 474)
No single metric tells the full story. See the ROCO:4735 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avita Corp is a manufacturer of point-of-care health products designed for clinical and personal use. The company provides body composition analyzers, blood pressure monitors, blood glucose monitors, digital thermometers, and nasal care devices. Its products include a thermometer, nasal aspirator, blood pressure monitor arm, and wrist.
72GF Score
Get the complete analysis for ROCO:4735
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4735 has been successfully added to your 
